Charité
Sapreme is collaborating with the research group of Prof. Hendrik Fuchs at the Charité – Universitätsmedizin in Berlin. His group has strong expertise in targeted delivery of macromolecular drugs into the cytosol of cells by use of endosomal escape enhancers. Sapreme is working with Charité to develop the ENDOSCAPE® technology for delivery of targeted toxins.
FUB
Sapreme is collaborating with the research group of Dr. Alexander Weng at the department of Prof. Matthias Melzig at the Freie Universität in Berlin (FUB). The group of Dr. Weng has considerable expertise in identifying and characterization of novel endosomal escape enhancers from natural sources and the development of non-viral gene carriers. Sapreme is working with the FUB to develop the ENDOSCAPE® technology for targeted delivery of DNA/RNA.
ENDOSCAPE consortium
Sapreme is working with a multidisciplinary consortium including 11 other academic and industrial parties on the development of a non-viral based gene therapy for cancer and haemophilia patients using Sapreme’s proprietary endosomal escape enhancers. The project is funded by the European Union (EU) through Horizon 2020.
Aglaia Oncology Funds
Aglaia Oncology Funds is an investment firm with a 100% focus on oncology. Aglaia Oncology Funds provides extensive know-how in cancer drug development and closely collaborates with inventors and entrepreneurs to develop early-stage technology into clinically and commercially successful biotech companies.